Volitionrx (VNRX) Common Equity (2019 - 2025)
Volitionrx (VNRX) has disclosed Common Equity for 9 consecutive years, with -$35.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Common Equity fell 58.79% year-over-year to -$35.9 million, compared with a TTM value of -$35.9 million through Sep 2025, down 58.79%, and an annual FY2024 reading of -$24.9 million, down 185.89% over the prior year.
- Common Equity was -$35.9 million for Q3 2025 at Volitionrx, down from -$33.1 million in the prior quarter.
- Across five years, Common Equity topped out at $31.2 million in Q1 2021 and bottomed at -$35.9 million in Q3 2025.
- Average Common Equity over 5 years is -$4.4 million, with a median of -$3.0 million recorded in 2023.
- The sharpest move saw Common Equity surged 239.27% in 2021, then crashed 694.03% in 2024.
- Year by year, Common Equity stood at $17.7 million in 2021, then crashed by 117.64% to -$3.1 million in 2022, then crashed by 178.62% to -$8.7 million in 2023, then tumbled by 185.89% to -$24.9 million in 2024, then tumbled by 44.33% to -$35.9 million in 2025.
- Business Quant data shows Common Equity for VNRX at -$35.9 million in Q3 2025, -$33.1 million in Q2 2025, and -$29.0 million in Q1 2025.